Elsevier BV provides LaTeX templates for many of its journals. Check this journal’s author guidelines, and we can convert your manuscript into its template.
LaTeX Template Conversion →01Impact factor
Impact factor of Clinical Lymphoma Myeloma & Leukemia (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Clinical Lymphoma Myeloma & Leukemia published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, calculated by ScholarsColab. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.
Rank in its subject categories
- Oncologyrank 320 of 347 journals
- Hematologyrank 97 of 104 journals
Ranks here compare journals of the same Web of Science category in our data by 2-year citedness; they are not the official JCR rank.
Quartile of Clinical Lymphoma Myeloma & Leukemia
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Clinical Lymphoma Myeloma & Leukemia is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Citations and papers per year
Article processing charge listed at about US$3,890.
Is your paper a fit for Clinical Lymphoma Myeloma & Leukemia?
Most desk rejections come from a scope mismatch. Compare your title and abstract with what this journal really publishes. Free, no sign-up, about 2 minutes.
Check my paper for this journalOr find journals that fit my paper
Need a faster review? The fastest journals in Oncology accept papers in a median of 3 days.
- Anti-Cancer Drugs 3 days
- Journal of Neuro-Oncology 41 days
- Current Breast Cancer Reports 42 days
APC waivers and discounts for Clinical Lymphoma Myeloma & Leukemia APC about US$3,890
Elsevier: automatic 100% waiver for Research4Life Group A and 50% for Group B in fully open access journals, but only when every author is in an eligible country. Authors in 82 countries get a full waiver.
02Retractions
Retractions and research integrity at Clinical Lymphoma Myeloma & Leukemia
Most common reasons (a retraction can have several):
Clinical Lymphoma Myeloma & Leukemia has 1 retracted paper on record, the latest in Jul 2020. A retraction count is not a verdict on a journal: large journals publish more and journals that investigate actively retract more. The trend and the reasons tell you more than the number.
03Funders
Who funds research published in Clinical Lymphoma Myeloma & Leukemia
Funders named most often
A high share of funded papers usually means the journal is a common choice for grant-supported work in its field. If your funder pays article processing charges, or your country qualifies for a waiver, check what applies to your author team with the free APC waiver checker.
04Indexing
Indexing of Clinical Lymphoma Myeloma & Leukemia
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Publisher
- Elsevier BV all its journals →
- Subjects
- Oncology, Hematology
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor on this page is calculated by ScholarsColab (see how the impact factor works).
Each link opens the official record for this journal, searched by its ISSN where we have one.
05How to submit
How to submit to Clinical Lymphoma Myeloma & Leukemia
- Read the guide for authors. It sets the article types, word limit, reference style and file format that Clinical Lymphoma Myeloma & Leukemia accepts. You find it on the official website of the journal, usually under "For authors" or "Submit".
- Use the journal's template. Elsevier BV offers Word and LaTeX templates for many of its journals. If your manuscript is in Word and the journal wants LaTeX, our LaTeX Template Conversion moves it into the template. If the language or structure needs work first, manuscript editing by a PhD editor in your field is priced by word count (see the editing cost guide).
- Check the fit. Read the aims and scope and a few recent issues; papers outside the scope are the most common reason for a desk rejection. The Journal Finder shows journals that published the closest work.
- Check the fee. Clinical Lymphoma Myeloma & Leukemia is not a fully open access journal, so authors usually pay nothing unless they choose open access for their article or the journal charges page or colour fees. The guide for authors states the current charges.
- Check your manuscript before you submit. The free Submission Readiness Check asks the seven questions our reviewers ask in every audit and takes about 2 minutes.
06Reviewer comments
Reviewer comments and rejection reasons for Clinical Lymphoma Myeloma & Leukemia
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Clinical Lymphoma Myeloma & Leukemia, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.
Audit my paper before I submit →Worried about the English? Manuscript editing by editors in your subject: see the price →
Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 seconds07Same subject
Oncology journals with a similar impact factor*
The journals next to Clinical Lymphoma Myeloma & Leukemia when the 328 journals of Oncology in our data are ranked by impact factor*:
| Rank | Journal | Impact factor* | Indexing | Open access |
|---|---|---|---|---|
| 316 | Psycho-Oncologie | 0.32 | SCIE | Subscription |
| 317 | Cancer Urology | 0.29 | ESCI | Some open access |
| 318 | Die Onkologie | 0.26 | SCIE | Subscription |
| 319 | Indian Journal of Medical and Paediatric Oncology | 0.26 | ESCI | Fully open access |
| 321 | Revista de Senología y Patología Mamaria | 0.22 | ESCI | Subscription |
| 322 | Revista Colombiana de Cancerología | 0.14 | ESCI | Some open access |
| 323 | Oncology | 0.13 | SCIE | Subscription |
| 324 | Hematology Transfusion and Cell Therapy | 0.12 | ESCI | Fully open access |
*Impact factor calculated by ScholarsColab (2-year citedness), not the official Clarivate value.
Is Clinical Lymphoma Myeloma & Leukemia right for your paper? Find the right journal
Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.
No AI or language model is used. Your words are matched against the titles of 157,375 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated by ScholarsColab, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time is the median days from submission to acceptance (not every publisher publishes these dates). Always check a journal’s scope and current indexing before submitting.
08Questions
Frequently asked questions
What is the impact factor of Clinical Lymphoma Myeloma & Leukemia?
Based on ScholarsColab citation data (October 2026), the 2-year impact factor of Clinical Lymphoma Myeloma & Leukemia is 0.25: papers it published in the two previous years were cited 0.25 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.
What is the h-index of Clinical Lymphoma Myeloma & Leukemia?
The h-index of Clinical Lymphoma Myeloma & Leukemia is 66 (October 2026): 66 of its papers have each been cited at least 66 times. Its i10-index is 1,395.
What is the APC of Clinical Lymphoma Myeloma & Leukemia?
The listed article processing charge (APC) is about US$3,890 for Clinical Lymphoma Myeloma & Leukemia (data from October 2026). APCs change and can differ by article type, country or discounts, so confirm the current charge on the journal’s website before submitting.
What is the quartile of Clinical Lymphoma Myeloma & Leukemia?
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Clinical Lymphoma Myeloma & Leukemia is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Is Clinical Lymphoma Myeloma & Leukemia indexed in Scopus?
Yes. Clinical Lymphoma Myeloma & Leukemia appears in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Clinical Lymphoma Myeloma & Leukemia an SCIE journal?
Yes. Clinical Lymphoma Myeloma & Leukemia is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Clinical Lymphoma Myeloma & Leukemia in Journal Citation Reports (JCR)?
Yes. Clinical Lymphoma Myeloma & Leukemia is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.
Does Clinical Lymphoma Myeloma & Leukemia offer an APC waiver?
Clinical Lymphoma Myeloma & Leukemia follows the policy of Elsevier: automatic 100% waiver for Research4Life Group A and 50% for Group B in fully open access journals, but only when every author is in an eligible country. Rules verified 27 October 2026; confirm on the publisher's page.
Has Clinical Lymphoma Myeloma & Leukemia retracted papers?
Yes. 1 retracted paper are on record for Clinical Lymphoma Myeloma & Leukemia, 1 of them in the last 10 years; the most common reasons are concerns/issues about data, error in results and/or conclusions. A retraction count alone is not a verdict on a journal; look at the trend and the reasons. Data updated October 2026.
Who funds research published in Clinical Lymphoma Myeloma & Leukemia?
6% of 200 recent research articles in Clinical Lymphoma Myeloma & Leukemia name a funder; the funders named most often are F. Hoffmann-La Roche Ltd, NIH, Deutsche Forschungsgemeinschaft.
Popular journals
- The Lancet
- Nature
- Science
- PLoS ONE
- Scientific Reports
- Journal of the American Chemical Society
- Journal of the Franklin Institute
- Physics Today
- Food Chemistry
- European Journal of Pharmacology
- Transplantation
- ACS Applied Materials and Interfaces
- Fuel
- Electrochimica Acta
- Neurology
- Chemical Engineering Journal
- Zootaxa
- Tetrahedron Letters
- British Journal of Surgery
- Journal of Molecular Structure
Browse all journals: indexing, impact factor and reviewer comments →